The 14th International Forum of The Japanese Society of Gastroenterology

DAY2

Time & Date: 9:00~17:00, Friday, April 25, 2025

Place: Room 5 (Ohgi)

Main Theme: "Advances in gastrointestinal and hepato-pancreato-biliary immune-mediated

inflammatory diseases"

1. Advance in autoimmune liver disease $(9:00\sim10:10)$

Moderators: Atsushi Tanaka (Department of Medicine, Teikyo University School of Medicine, Japan)

Atsumasa Komori (Clinical Research Center, NHO Nagasaki Medical Center, Japan)

IF1-1 Therapeutic developments in autoimmune liver diseases

(Department of Transplantation Medicine, Division of Surgery and

Specialized Medicine, Oslo University Hospital, Norway)

Tom Hemming Karlsen

IF1-2 Recompensation Criteria in Patients with Autoimmune Hepatitis-Related decompensated Cirrhosis

(Department of Gastroenterology, Renji Hospital, Shanghai Jiao Tong

University, China)

Xiong Ma

IF1-3 The gut-liver axis in primary sclerosing cholangitis

(Division of Gastroenterology and Hepatology, Keio University School of

Medicine, Tokyo, Japan)

Nobuhiro Nakamoto, Masataka Ichikawa, Haruka Okada,

Nobuhito Taniki. Takanori Kanai

IF1-4 Identification of novel autoantibody using human protein microarray in patients with autoimmune hepatitis

(Department of Gastroenterology, Fukushima Medical University School of Medicine, Japan)

Kazumichi Abe, Jun Wada, Naoto Abe, Tatsuro Sugaya,

Yosuke Takahata, Masashi Fujita, Manabu Hayashi, Hiromasa Ohira

2. Advances in immune-related pancreaticobiliary disease $(10:20\sim11:30)$

Moderators: Yuzo Kodama (Department of Gastroenterology, Kobe University Graduate School of Medicine, Japan)

Hiroyuki Isayama (Department of Gastroenterology, Juntendo University, Japan)

IF2-1 Exploring clinical subtypes and treatment strategies of IgG4-related disease (Department of Rheumatology, Peking Union Medical College Hospital, China)

Wen Zhang, Linyi Peng, Jiaxin Zhou, Yunyun Fei, Yuxue Nie

IF2-2 Proximal versus Distal IgG4-Sclerosing Cholangitis: Distinct Disease Entities?

(Department of Gastroenterology, University of Ulsan College of Medicine,
Asan Medical Center, Korea)

Tae Jun Song

IF2-3 Advances in immune-related pancreaticobiliary disease

(Department of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine, Japan)

Masahiro Shiokawa, Masataka Yokode, Takeshi Kuwada,

Yoshihiro Nishikawa, Yuya Muramoto, Hiroshi Seno

IF2-4 The 2024 diagnostic criteria for primary sclerosing cholangitis

(Department of Gastroenterology, Nagoya City University Midori Municipal Hospital, Japan)

Itaru Naitoh

(Department of Gastroenterology, Graduate School of Medicine, Juntendo University, Japan)

Hirovuki Isavama

(Department of Medicine, Teikyo University School of Medicine, Japan)

Atsushi Tanaka

3. Advances in inflammatory bowel disease $(14:30\sim15:40)$

Moderators: Tadakazu Hisamatsu (Department of Gastroenterology and Hepatology, Kyorin University School of Medicine, Japan)

Akira Andoh (Department of Gastroenterology, Shiga University of Medical Science, Japan)

IF3-1 Optimization the non-invasive tools to predict endoscopic severity for IBD patients

(Department of Internal Medicine, National Taiwan University Hospital, Taiwan)

Shu-Chen Wei

IF3-2 Redox-induced Stabilization of AMBRA1 by USP7 Promotes Intestinal Oxidative Stress and Colitis through Antagonizing DUB3-mediated NRF2 Deubiquitination

(Department of Gastroenterology, Rui Jin Hospital, affiliate to Shanghai Jiao

Tong University, school of Medicine, China.)

Yubei Gu

(Department of Colorectal Surgery, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, China)

Xu Weimin, Hua Zhebin, Wang Yaosheng, Liu Chen Ying, Du Peng

IF3-3 Subcutaneous infliximab for the treatment of inflammatory bowel disease

(Department of Gastroenterology and Inflammatory Bowel Disease Center, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea) Byong Duk Ye

The 14th

IF3-4 The involvement of MEFV gene mutation in the pathophysiology of inflammatory bowel disease unclassified.

(Department of Gastroenterology and Hepatology, Sapporo Medical

University School of Medicine, Japan)
Hiroshi Nakase, Kohei Wagatsuma

4. Advances in immune-related adverse event (15:50~17:00)

Moderators: Yasuo Hamamoto (Department of Medical Oncology, Institute of Science Tokyo, Japan)

Hayato Nakagawa (Department of Gastroenterology and Hepatology, Mie University, Japan)

- IF4-1 Cancer immunotheray and immune-related adverse events ~lessons learned (Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan/Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan/Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan)

 Chih-Hung Hsu
- IF4-2 Friend or Foe? Advances in the management of irAE (Department of Clinical Oncology, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong)
 Ka On Lam
- IF4-3 Appropriate management of patients with immune-related gastrointestinal/hepatobiliary adverse events associated with immune checkpoint inhibitors.

 (Division of General Internal Medicine, Mitsui Memorial Hospital, Japan)
 Nobuyoshi Minemura
- IF4-4 irAE minimal requirements to know as an oncologist
 (Nara Prefecture General Medical Center, Japan)
 Teruhisa Azuma